Mexican Chronic Renal Insufficiency Cohort Study

描述（由研究者提供）：拟议的墨西哥慢性肾功能不全队列研究是由美国NIH资助的研究者James P. Lash（医学博士）和Magdalena Madero（医学博士）（墨西哥城伊格纳西奥查韦斯国家心脏病研究所的肾病学家）合作进行的。在墨西哥，慢性肾脏病（CKD）是一个日益严重的公共卫生问题，在过去10年中，患病率每年增加11%。此外，CKD是墨西哥住院死亡的第三大常见原因。尽管这个问题很严重，但人们对墨西哥慢性肾脏病的流行病学知之甚少。更好地了解CKD进展的风险因素至关重要，因为墨西哥不到一半的肾衰竭患者可以接受透析或肾移植。本申请的总体目标是招募和保留340名 患有轻度至中度CKD的墨西哥人。在支持期间产生的初步数据将用于申请院外资金，以延长受试者随访，以实现以下长期特定目标：1）确定墨西哥CKD患者肾脏疾病进展的风险因素; 2）确定心血管事件和亚临床心血管疾病进展的风险因素; 3）评估CKD与其他临床结果如功能状态、生活质量和抑郁之间的关联;和4）比较居住在墨西哥的墨西哥CKD患者和居住在美国的墨西哥CKD患者的CKD进展率。积极的NIDDK资助的研究计划，重点是调查美国西班牙裔和非西班牙裔的CKD流行病学（首席研究员Lash，R 01 DK 72231和U 01 DK 60980）和伊利诺伊大学芝加哥公共卫生学院提供的广泛培训资源。该应用程序通过在墨西哥建立流行病学CKD研究能力并为Madero博士和她所在机构的其他学员提供研究方法培训，实现了Fogarty国际研究合作奖计划的使命。此外，研究获得的知识有可能为未来干预性试验的设计提供信息，以改善墨西哥CKD患者的健康结局。

DESCRIPTION (provided by investigator): The proposed Mexican Chronic Renal Insufficiency Cohort Study is collaboration between a U.S. based NIH- funded investigator, James P. Lash, MD and Magdalena Madero, MD, a nephrologist at the Instituto Nacional de Cardiologia Ignacio Chavez in Mexico City. In Mexico, chronic kidney disease (CKD) represents a growing public health problem, with an increase in prevalence of 11% per year in the last 10 years. Furthermore, CKD is the third most common cause of in-hospital mortality in Mexico. Despite the magnitude of this problem, little is known about the epidemiology of CKD in Mexico. A better understanding of risk factors for progression of CKD is of critical importance because less than one-half of patients with kidney failure in Mexico have access to dialysis or kidney transplantation. The overall objective of this application is to recruit and retain a cohort of 340 Mexicans with mild-to-moderate CKD. Preliminary data generated during the period of support will be utilized to apply for extramural funding to extend participant follow-up in order to accomplish the following long- term Specific Aims: 1) Identify risk factors for progression of kidney disease in Mexicans with CKD; 2) Identify risk factors for cardiovascular events and progression of subclinical cardiovascular disease; 3) Evaluate the association between CKD and other clinical outcomes such as functional status, quality of life, and depression; and 4) Compare rates of CKD progression between Mexicans with CKD living in Mexico and Mexicans with CKD living in the U.S. The proposed study will leverage the infrastructure of an active NIDDK-funded research program which is focused on investigating the epidemiology of CKD in U.S. Hispanics and non-Hispanics (Principal Investigator Lash, R01 DK72231, and U01 DK60980) and the extensive training resources available at the University of Illinois at Chicago School of Public Health. This application fulfills the mission of the Fogarty International Research Collaboration Award program by building epidemiologic CKD research capabilities in Mexico and providing training in research methodology for Dr. Madero and other trainees at her institution. Furthermore, the knowledge gained by the research has the potential to inform the design of future interventional trials with the goal of improving health outcomes for Mexicans with CKD.